|
The effect of inhibition of interleukin 6 along with the drug doxorubicin on gene expression BIM, BAX, Bcl-2
|
Mahsa Nikdel Khosroshahi    , Simin Namvar aghdash * , Farhad Jadidi Niaragh |
| Department of Biology, Faculty of basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran , siminnamvar2@gmail.com |
|
|
Abstract: (1007 Views) |
Despite current treatments such as chemotherapy, many people around the world still die from breast cancer disease every year, which is mainly due to drug resistance in breast tumor cells and tumor recurrence. Also, the side effects caused by chemotherapy drugs are sometimes very severe, and it is necessary to reduce the required dose of these drugs with different methods. Interleukin 6 (IL-6) is one of the molecules that play a significant role in the development of breast cancer and drug resistance in breast tumor cells, and its inhibition can help in the treatment of this malignancy. Doxorubicin (DOX) is one of the common chemotherapy drugs that prevents tumor progression by interfering with DNA replication and transcription. In the present study, chitosan lactate (CL) nanoparticles were used for simultaneous delivery of DOX and anti-IL-6 siRNA molecules to 4T1 mouse breast cancer cells. Nanocarriers protect the drug from degradation and increase its half-life in the bloodstream and increase the solubility of hydrophobic drugs. Also, by specifically targeting the tumor, these carriers increase the drug concentration at the tumor site and reduce the toxicity of the drugs for other normal cells of the body. CL nanoparticles were synthesized by "ionic gelation" method. After evaluating the characteristics, the CL nanoparticles and CL+DOX, CL+siRNA and CL+DOX+siRNA formulations, as well as free DOX, were transferred to cultured 4T1 cells. Then, their effects on this cell line were investigated. Among these evaluations, MTT, CAM, scratch test, colony formation test, evaluation of related gene expression and measurement of interleukin-6 protein levels can be mentioned. The results showed that CL + DOX + siRNA nanoparticles have the highest toxicity and inhibitory effect on 4T1 cancer cells, compared to when each of the nanoparticles containing siRNA and DOX and DOX were applied separately. Also, the combined treatment significantly reduced the angiogenesis rate and the size of the tumors created by 4T1 cells. Therefore, based on these results, it can be resulted that CL nanoparticles loaded with DOX and anti-IL-6 siRNA can be considered as an effective formulation in the treatment of breast cancer. |
|
| Keywords: Breast cancer, IL-6, siRNA, Doxorubicin, 4T1 cell line |
|
|
Full-Text [PDF 599 kb]
(155 Downloads)
|
Type of Study: Research |
Subject:
Divers
Received: 2024/12/28 | Accepted: 2025/03/1 | Published: 2025/09/4
|
|
|
|
|
|
|
| References |
1. Al-Malky, H.S., Al Harthi, S. E. and A.-M. M. Osman, (2020). Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance, Journal of Oncology Pharmacy Practice, 26(2), 434-444. http://doi.org/10.1177/1078155219877931 [ DOI:10.1177/1078155219877931] [ PMID] 2. Bray, F., Laversanne, M., Weiderpass, E. and Soerjomataram, I. (2021). The ever‐increasing importance of cancer as a leading cause of premature death worldwide, Cancer, 127(16), 3029-3030. [ DOI:10.1002/cncr.33587] [ PMID] 3. Chen, Y., Shi, S. and Dai, Y. (2022). Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy, Biomedicine & Pharmacotherapy, 156, 113903. http://doi.org/10.1016/j.biopha.2022.113903 [ DOI:10.1016/j.biopha.2022.113903] [ PMID] 4. Gao, Z.G., Tian, L., Hu, J., Park, I.S. and Bae, Y.H. (2011). Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles, Journal of controlled release, 152(1), 84-89. http://doi.org/10.1016/j.jconrel.2011.01.021 [ DOI:10.1016/j.jconrel.2011.01.021] [ PMID] [ PMCID] 5. Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L. A., Minihan A., et al., (2022) Breast cancer statistics, 72(6), 524-541. http:// doi.org/10.3322/caac.21754 [ DOI:10.3322/caac.21754] [ PMID] 6. Grady, W.M. (2021). Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer, Advances in cancer research, 151, 425-468. http://doi.org/10.1016/bs.acr.2021.02.006 [ DOI:10.1016/bs.acr.2021.02.006] [ PMID] 7. Khodakarami, A., Darvishi, S., Hassannia, H., Sadeghi, M., Esmaeeli, S., Hashemi V. et al., (2023). Blockade of CD155 and interleukin-6 suppresses breast cancer cell growth, International Journal of Drug Research in Clinics. 1, 2. http://doi.org/10.34172/ijdrc.2023.e10 [ DOI:10.34172/ijdrc.2023.e10] 8. Mao H, Gu H, Qu X, Sun J, Song B, Gao W, et al, 2013. "Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. http://doi.org/10.3892/ijmm.2012.1176 [ DOI:10.3892/ijmm.2012.1176] [ PMID] 9. Masjedi, A., Ahmadi, A., Atyabi, F., Farhadi, S., Irandoust, M., Khazaei-Poul Y. et al, (2020). Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N, N, N-trimethyl chitosan nanoparticles potently reduces cancer cell progression, International journal of biological macromolecules, 149, 487-500http://doi.org/10.1016/j.ijbiomac.2020.01.273 [ DOI:10.1016/j.ijbiomac.2020.01.273] [ PMID] 10. Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi M. et al, (2018). The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, Biomedicine & Pharmacotherapy, 108, 1415-1424. http://doi.org/10.1016/j.biopha.2018.09.177 [ DOI:10.1016/j.biopha.2018.09.177] [ PMID] 11. Mayrovitz, H. N. (2022). Breast Cancer. http://doi.org/10.1002/cncr.33587 [ DOI:10.1002/cncr.33587] [ PMID] 12. Park, M., Kim, D., Ko, S., Kim, A., Mo, K. and Yoon H., (2022). Breast cancer metastasis: Mechanisms and therapeutic implications, International Journal of Molecular Sciences, 23(12), 6806. http://doi.org/10.3390/ijms23126806 [ DOI:10.3390/ijms23126806] [ PMID] [ PMCID] 13. Pulaski B.A. and Ostrand‐Rosenberg, S. (2000). Mouse 4T1 breast tumor model," Current protocols in immunology, 39(1), 1-16. [ DOI:10.1002/0471142735.im2002s39] [ PMID] 14. Qiu, H., Cao S., and Xu, R. (2020). Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. 41(10), 1037-1048. http://doi.org/ 10.1002/cac2.12197 [ DOI:10.1002/cac2.12197] [ PMID] [ PMCID] 15. Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy, Journal of cancer research and therapeutics, 10(4), 853-858. http://doi.org/ 10.4103/0973-1482.139267 [ DOI:10.4103/0973-1482.139267] [ PMID] 16. Salimifard, S., Karoon Kiani, F., Sadat Eshaghi, F., Izadi S., Shahdadnejad, K., Masjedi A. et al., (2020). Retraction notice to Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. Life Sciences, 260, 118423. http://doi.org/10.1016/j.lfs.2024.122774 [ DOI:10.1016/j.lfs.2024.122774] [ PMID] 17. Shi, Z., Yang, W.M., Chen, L.P., Yang, D.H., Zhou, Q., Zhu, J. et al., (2012). Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production, Breast cancer research and treatment, 135, 737-747. http://doi.org/10.1007/s10549-012-2196-0 [ DOI:10.1007/s10549-012-2196-0] [ PMID] 18. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal A., et al., (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 71(3), 209-249. http://doi.org/10.3322/caac.21660 [ DOI:10.3322/caac.21660] [ PMID] 19. Tao K., Fang M., Alroy J., and Sahagian, G.G. (2008). Imagable 4T1 model for the study of late stage breast cancer, BMC cancer, 8(1), 1-19. http://doi.org/10.1186/1471-2407-8-228 [ DOI:10.1186/1471-2407-8-228] [ PMID] [ PMCID] 20. Wallace, K.B., Sardão, V.A. and Oliveira, P.J. (2020). Mitochondrial determinants of doxorubicin-induced cardiomyopathy, Circulation research, 126(7), 926-941. [ DOI:10.1161/CIRCRESAHA.119.314681] [ PMID] [ PMCID] 21. Ye, Z., Hao, R., Cai, Y., Wang, X., Huang, G., (2016). Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(4), 4509-15. http://doi.org/10.1016/j.biopha.2022.113903 [ DOI:10.1016/j.biopha.2022.113903] [ PMID] |
|
| Add your comments about this article |
|
|
|
|
Nikdel Khosroshahi M, namvar aghdash S, Jadidi Niaragh F. The effect of inhibition of interleukin 6 along with the drug doxorubicin on gene expression BIM, BAX, Bcl-2. gebsj 2025; 13 (2) :246-255 URL: http://gebsj.ir/article-1-507-en.html
|
